Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17254977 | CXCL13 Marker For Predicting Immunotherapeutic Responsiveness In Patient With Lung Cancer And Use Thereof | December 2020 | July 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17122102 | METHODS FOR PREDICTING RESPONSE TO TREATMENT | December 2020 | October 2023 | Abandon | 34 | 0 | 1 | No | No |
| 17104336 | METHOD OF DETECTING SMALL RNA | November 2020 | June 2024 | Allow | 43 | 4 | 1 | Yes | No |
| 17099195 | AUTISM ASSOCIATED GENETIC MARKERS | November 2020 | July 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17094190 | USE OF POOLED SAMPLES TO OPTIMISE THE EFFICIENCY AND UTILITY OF A RAPID, LAB-FREE POINT-OF-CARE TEST | November 2020 | February 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17087277 | CITRUS GREENING (HUANGLONGBING)-INDUCED SMALL RNAS ARE POTENTIAL EARLY DIAGNOSIS MARKERS | November 2020 | May 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17048131 | ASSESSMENT OF THE RISK OF COMPLICATION IN A PATIENT SUSPECTED OF HAVING AN INFECTION, HAVING A SOFA SCORE LOWER THAN TWO | October 2020 | August 2024 | Abandon | 46 | 1 | 1 | No | No |
| 17061749 | MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCE | October 2020 | May 2021 | Allow | 7 | 1 | 1 | Yes | No |
| 16948526 | METHODS AND COMPOSITIONS FOR ASSAYING REPETITIVE SEQUENCES | September 2020 | July 2024 | Allow | 46 | 2 | 1 | No | No |
| 16955187 | METHOD FOR DIAGNOSING BACTERIAL VAGINOSIS BY DETECTING METHANOBREVIBACTER SMITHII | September 2020 | March 2024 | Abandon | 45 | 2 | 1 | No | No |
| 16975651 | SNP MOLECULAR MARKER TIGHTLY LINKED TO WEEPING TRAIT OF MEI AND DETECTION METHOD AND USE THEREOF | August 2020 | January 2024 | Abandon | 40 | 2 | 1 | No | No |
| 16992005 | METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS | August 2020 | June 2024 | Abandon | 46 | 0 | 1 | No | No |
| 16935761 | METHODS AND COMPOSITIONS FOR DETECTION OF ENTEROVIRUS D68 | July 2020 | July 2023 | Allow | 36 | 2 | 0 | No | No |
| 16928436 | METHODS FOR PREDICTING RISK OF INTERSTITIAL PNEUMONIA | July 2020 | January 2024 | Allow | 42 | 1 | 1 | No | No |
| 16866137 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | May 2020 | June 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16756702 | METHODS AND COMPOSITIONS FOR USE OF TREX2 AS DIAGNOSTIC AND PROGNOSTIC MARKER FOR CANCER | April 2020 | August 2024 | Abandon | 52 | 2 | 1 | No | No |
| 16847334 | USE OF GLYCANS AND GLYCOSYLTRANSFERASES FOR DIAGNOSING/MONITORING INFLAMMATORY BOWEL DISEASE | April 2020 | January 2024 | Abandon | 45 | 2 | 1 | No | No |
| 16651492 | INTERLEUKIN 32 AS A BIOMARKER OF TYPE 1 DIABETES | March 2020 | February 2024 | Abandon | 46 | 3 | 1 | Yes | Yes |
| 16826030 | AUTISM ASSOCIATED GENETIC MARKERS | March 2020 | December 2022 | Abandon | 33 | 0 | 1 | No | No |
| 16805125 | TERTIARY AMINE SUBSTITUTED COUMARIN COMPOUNDS AND USES AS FLUORESCENT LABELS | February 2020 | June 2024 | Allow | 51 | 2 | 2 | Yes | No |
| 16641544 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS | February 2020 | May 2024 | Abandon | 51 | 2 | 2 | No | No |
| 16789383 | Therapeutic Regimen for Hypertension | February 2020 | January 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 16784051 | MOLECULAR GENETIC APPROACH TO TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG DEPENDENCE | February 2020 | January 2022 | Allow | 23 | 1 | 0 | No | No |
| 16773040 | GENETIC MARKERS FOR PREDICTING RESPONSIVENESS TO THERAPY WITH HDL-RAISING OR HDL MIMICKING AGENT | January 2020 | March 2022 | Allow | 26 | 1 | 0 | No | No |
| 16633768 | METHODS AND TOOLS FOR PURIFYING NUCLEIC ACIDS AND USING POLYMERIZED TUBULIN | January 2020 | May 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16745998 | DIAGNOSTIC TEST FOR PREDICTING METASTASIS AND RECURRENCE IN CUTANEOUS MELANOMA | January 2020 | June 2022 | Allow | 29 | 2 | 0 | No | No |
| 16736208 | DIAGNOSTIC AND PROGNOSTIC TEST FOR STURGE-WEBER SYNDROME, KLIPPEL-TRENAUNAY-WEBER SYNDROME, AND PORT-WINE STAINS (PWSS) | January 2020 | November 2023 | Abandon | 46 | 4 | 1 | No | No |
| 16628259 | METHOD FOR DETECTING PARASITIC INFECTION AND KIT | January 2020 | March 2023 | Allow | 38 | 3 | 1 | Yes | No |
| 16726546 | KIT FOR IN VITRO TESTING PANEL OF GENES IN PAP SMEAR SAMPLES FOR ENDOMETRIOSIS AND METHOD OF NON-INVASIVELY AND QUALITATIVELY DETERMINING SEVERITY OF ENDOMETRIOSIS USING THE KIT | December 2019 | June 2023 | Abandon | 41 | 2 | 1 | Yes | No |
| 16724970 | TERT PROMOTER MUTATIONS IN CANCER | December 2019 | June 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16481331 | PROSTATIC CANCER MARKER, PLXNA1, AND APPLICATION THEREOF | November 2019 | February 2023 | Abandon | 43 | 1 | 2 | No | No |
| 16610895 | TRANSMEMBRANE PORE CONSISTING OF TWO CSGG PORES | November 2019 | February 2024 | Allow | 51 | 3 | 1 | Yes | No |
| 16664505 | Consensus Coding Sequences of Human Breast and Colorectal Cancers | October 2019 | March 2023 | Abandon | 41 | 0 | 1 | No | No |
| 16662939 | ERBB2/HER2 MUTATIONS IN THE TRANSMEMBRANE OR JUXTAMEMBRANE DOMAIN | October 2019 | March 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16606665 | PEROXISOME BIOMARKERS IN HIV DISEASE PROGRESSION AND PEROXISOME ACTIVATING DRUGS FOR HIV TREATMENT | October 2019 | July 2023 | Allow | 45 | 2 | 1 | Yes | No |
| 16601627 | DIAGNOSIS AND TREATMENT OF VIRAL DISEASES | October 2019 | April 2024 | Allow | 54 | 4 | 2 | No | No |
| 16499908 | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING AN IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER | October 2019 | September 2023 | Allow | 48 | 4 | 1 | No | No |
| 16580523 | DISCOVERY OF A SOMATIC MUTATION IN MYD88 GENE IN LYMPHOPLASMACYTIC LYMPHOMA | September 2019 | April 2023 | Allow | 42 | 2 | 1 | No | Yes |
| 16569119 | GENE EXPRESSION PROFILES ASSOCIATED WITH SUB-CLINICAL KIDNEY TRANSPLANT REJECTION | September 2019 | March 2024 | Allow | 54 | 2 | 1 | Yes | No |
| 16564886 | PREDICTION AND TREATMENT OF HEART FAILURE | September 2019 | May 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16534028 | NON-INVASIVE TEST TO PREDICT RECURRENCE OF COLORECTAL CANCER | August 2019 | September 2023 | Allow | 49 | 4 | 1 | Yes | No |
| 16530416 | BIOMARKER DLEC1 FOR CANCER | August 2019 | March 2023 | Allow | 44 | 3 | 1 | Yes | No |
| 16477456 | METHODS AND KITS FOR TREATING CARDIOVASCULAR DISEASE | July 2019 | March 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16453195 | ncRNA AND USES THEREOF | June 2019 | March 2022 | Allow | 33 | 2 | 1 | No | No |
| 16451942 | METHOD FOR EVALUATING WHETHER AN INDIVIDUAL WITH CANCER IS SUITABLE FOR TREATMENT WITH A CDK INHIBITOR | June 2019 | June 2023 | Allow | 48 | 1 | 1 | No | No |
| 16471320 | KIT FOR IDENTIFYING MALIGNANCY, AND USES THEREOF | June 2019 | January 2023 | Allow | 43 | 2 | 1 | Yes | No |
| 16445322 | ADM2 GENE MARKER FOR DIAGNOSIS OR PROGNOSIS PREDICTION OF THYROID CANCER AND USES THEREOF | June 2019 | April 2023 | Abandon | 46 | 3 | 1 | No | No |
| 16462469 | METHOD FOR PREDICTING SENSITIVITY OF CANCER TO TREATMENT WITH PD-1 IMMUNE CHECKPOINT INHIBITOR | May 2019 | April 2024 | Abandon | 59 | 3 | 1 | No | No |
| 16416083 | PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY BIOMARKERS | May 2019 | December 2021 | Abandon | 31 | 1 | 1 | Yes | No |
| 16409520 | Compositions and Methods to Detect Kidney Fibrosis | May 2019 | September 2024 | Abandon | 60 | 4 | 1 | Yes | No |
| 16346659 | METHOD FOR THE IN VITRO PROGNOSIS OF INDIVIDUALS HAVING MULTIPLE MYELOMA AND METHOD FOR THE TREATMENT THEREOF | May 2019 | August 2022 | Allow | 39 | 2 | 1 | No | No |
| 16395087 | METHODS OF USING GENETIC MARKERS ASSOCIATED WITH ENDOMETRIOSIS | April 2019 | October 2022 | Abandon | 42 | 2 | 2 | No | No |
| 16369724 | BIOMARKERS FOR INFLAMMATORY SKIN DISEASE | March 2019 | October 2022 | Allow | 42 | 2 | 1 | Yes | No |
| 16335830 | ASSAY FOR DISTINGUISHING BETWEEN SEPSIS AND SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | March 2019 | August 2023 | Abandon | 53 | 2 | 2 | No | No |
| 16356693 | METHODS FOR PERSONALIZED DETECTION OF THE RECURRENCE OF CANCER OR METASTASIS AND/OR EVALUATION OF TREATMENT RESPONSE | March 2019 | January 2023 | Abandon | 46 | 3 | 0 | No | No |
| 16355796 | Method and System for Automated Image Analysis in Cancer Cells | March 2019 | August 2021 | Allow | 29 | 3 | 0 | Yes | No |
| 16354799 | TISSUE-SPECIFIC METHYLATION MARKER | March 2019 | September 2023 | Allow | 54 | 3 | 1 | Yes | No |
| 16333177 | RNA BIOMARKERS FOR HEREDITARY ANGIOEDEMA | March 2019 | September 2023 | Allow | 54 | 4 | 1 | No | No |
| 16331792 | METHODS AND COMPOSITIONS FOR PREDICTING CHRONIC LUNG ALLOGRAFT DYSFUNCTION | March 2019 | December 2020 | Allow | 21 | 2 | 1 | Yes | No |
| 16287607 | METHODS FOR ASSESSING RISK OF INCREASED TIME-TO-FIRST-CONCEPTION | February 2019 | January 2021 | Abandon | 23 | 0 | 0 | No | No |
| 16281750 | METHODS FOR TREATING EOSINOPHILIC ESOPHAGITIS | February 2019 | April 2023 | Allow | 50 | 2 | 1 | Yes | No |
| 16327060 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF LYMPHATIC SYSTEM DISORDERS | February 2019 | March 2022 | Allow | 36 | 2 | 1 | Yes | No |
| 16281315 | METHODS FOR PROSTATE CANCER DETECTION AND TREATMENT | February 2019 | March 2022 | Allow | 37 | 1 | 1 | No | No |
| 16253697 | METHODS FOR COLON CANCER DETECTION AND TREATMENT | January 2019 | April 2022 | Allow | 38 | 1 | 1 | No | No |
| 16316662 | COMPOSITION FOR DIAGNOSING OR PREDICTING RISK OF METABOLIC SYNDROME OR METABOLIC SYNDROME-RELATED DISEASES USING HUMAN ORAL MICROBIOME | January 2019 | March 2022 | Allow | 38 | 3 | 1 | Yes | No |
| 16313231 | SWARM INTELLIGENCE-ENHANCED DIAGNOSIS AND THERAPY SELECTION FOR CANCER USING TUMOR- EDUCATED PLATELETS | December 2018 | July 2021 | Abandon | 31 | 0 | 1 | No | No |
| 16312958 | Compositions and Methods for Providing a Prognosis for Influenza Infection | December 2018 | May 2022 | Allow | 41 | 2 | 1 | No | No |
| 16225356 | METHOD AND KIT FOR GENETIC ANALYSIS | December 2018 | December 2021 | Abandon | 36 | 1 | 1 | No | No |
| 16309763 | CHICKEN WHOLE-GENOME SNP CHIP AND USE THEREOF | December 2018 | December 2022 | Allow | 48 | 1 | 0 | No | No |
| 16216846 | BIOMARKERS FOR USE IN PROGNOSIS OF MORTALITY IN CRITICALLY ILL PATIENTS | December 2018 | January 2023 | Allow | 50 | 2 | 2 | Yes | No |
| 16209698 | Inhibition of JAK-STAT Signaling Inhibits Formation of Neutrophil Extracellular Traps (NETs) | December 2018 | April 2022 | Allow | 40 | 2 | 2 | Yes | No |
| 16205659 | ANELLOVIRUS GENOME QUANTIFICATION AS A BIOMARKER OF IMMUNE SUPPRESSION | November 2018 | April 2024 | Allow | 60 | 5 | 0 | Yes | No |
| 16203803 | PREDICTING PEPTIDE RECEPTOR RADIOTHERAPY USING A GENE EXPRESSION ASSAY | November 2018 | May 2023 | Allow | 54 | 1 | 1 | No | No |
| 16304461 | DETERMINATION OF GENETIC PREDISPOSITION TO AGGRESSIVE PROSTATE CANCER | November 2018 | October 2023 | Abandon | 58 | 2 | 2 | No | No |
| 16197593 | METHODS AND COMPOSITIONS FOR DIAGNOSING, PROGNOSING, AND TREATING ENDOMETRIOSIS | November 2018 | February 2022 | Allow | 39 | 2 | 1 | No | No |
| 16303033 | DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE BASED ON GENES | November 2018 | September 2022 | Allow | 46 | 2 | 1 | No | No |
| 16192008 | STROMAL GENE SIGNATURES FOR DIAGNOSIS AND USE IN IMMUNOTHERAPY | November 2018 | October 2022 | Abandon | 47 | 2 | 1 | Yes | No |
| 16302015 | BTK MUTATION AND IBRUTINIB RESISTANCE | November 2018 | May 2021 | Allow | 30 | 2 | 1 | Yes | No |
| 16184748 | Methods of Subtyping CRC and their association with Treatment of Colon Cancer Patients With Oxaliplatin | November 2018 | March 2020 | Abandon | 16 | 1 | 0 | No | No |
| 16098019 | Methods and Compositions for Classifying DLBCL | October 2018 | May 2021 | Allow | 31 | 1 | 1 | No | No |
| 16158823 | METHOD FOR DETECTING CYSTIC FIBROSIS | October 2018 | November 2020 | Allow | 25 | 2 | 1 | No | No |
| 16153094 | BCR-ABL TRUNCATION MUTATIONS | October 2018 | January 2022 | Allow | 40 | 3 | 0 | Yes | No |
| 16149560 | METHODS AND COMPOSITIONS FOR SCD, CRT, CRT-D, OR SCA THERAPY IDENTIFICATION AND/OR SELECTION | October 2018 | December 2021 | Allow | 39 | 3 | 1 | Yes | No |
| 16138449 | METHOD FOR DETERMINING THE RISK OF DEVELOPING ACUTE KIDNEY INJURY IN A HUMAN SUBJECT WITH ACUTE MYOCARDIAL INFARCTION AND INHIBITING SUCH DEVELOPMENT | September 2018 | March 2022 | Allow | 41 | 2 | 1 | Yes | No |
| 16086144 | METHOD FOR DETECTING GENE MUTATION | September 2018 | April 2023 | Allow | 55 | 3 | 1 | No | No |
| 16110964 | URINE BIOMARKERS FOR DETECTING GRAFT REJECTION | August 2018 | February 2021 | Allow | 30 | 2 | 1 | No | No |
| 16109551 | COMPOSITIONS AND METHODS FOR DETECTION OF DRUG RESISTANT MYCOBACTERIUM TUBERCULOSIS | August 2018 | January 2021 | Allow | 29 | 1 | 1 | No | No |
| 16101078 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | August 2018 | December 2021 | Allow | 40 | 2 | 2 | No | No |
| 16076239 | GENE SIGNATURE PREDICTIVE OF HEPATOCELLULAR CARCINOMA RESPONSE TO TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE) | August 2018 | December 2021 | Allow | 40 | 2 | 1 | Yes | No |
| 16074728 | COPANLISIB BIOMARKERS | August 2018 | November 2022 | Abandon | 52 | 3 | 2 | Yes | No |
| 16071289 | COMPOSITIONS AND METHODS FOR SCREENING AND IDENTIFYING CLINICALLY AGGRESSIVE PROSTATE CANCER | July 2018 | September 2023 | Allow | 60 | 4 | 1 | Yes | No |
| 16069332 | IL-10 AS A PREDICTIVE BIOMARKER OF RESPONSIVENESS TO HOUSE DUST MITE ALLERGEN IMMUNOTHERAPY | July 2018 | February 2021 | Allow | 31 | 2 | 1 | Yes | No |
| 16031384 | BIOMARKERS FOR ASSESSING IDIOPATHIC PULMONARY FIBROSIS | July 2018 | November 2020 | Allow | 28 | 2 | 1 | No | No |
| 16028937 | METHODS FOR THE DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE | July 2018 | April 2021 | Allow | 33 | 2 | 1 | Yes | No |
| 16067235 | PREDICTING RESPONSE TO IMMUNOMODULATORY DRUGS (IMIDS) IN MULTIPLE MYELOMA PATIENTS | June 2018 | September 2020 | Abandon | 27 | 0 | 1 | No | No |
| 16066876 | COMPOSITIONS AND METHODS FOR SCREENING AND DIAGNOSIS OF PROSTATE CANCER | June 2018 | March 2021 | Allow | 32 | 1 | 1 | Yes | No |
| 16005207 | MATERIALS AND METHODS FOR ASSESSMENT OF COLORECTAL ADENOMA | June 2018 | July 2019 | Abandon | 13 | 1 | 0 | No | No |
| 15991247 | GENETIC POLYMORPHISMS ASSOCIATED WITH PSORIASIS, METHODS OF DETECTION AND USES THEREOF | May 2018 | October 2020 | Allow | 28 | 1 | 1 | No | No |
| 15990301 | C-CBL MUTATIONS AND USES THEREOF | May 2018 | March 2022 | Allow | 46 | 2 | 1 | No | No |
| 15987235 | ARID1A AND PPP2R1A MUTATIONS IN CANCER | May 2018 | March 2019 | Abandon | 9 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SITTON, JEHANNE SOUAYA.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 5.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SITTON, JEHANNE SOUAYA works in Art Unit 1634 and has examined 769 patent applications in our dataset. With an allowance rate of 33.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner SITTON, JEHANNE SOUAYA's allowance rate of 33.2% places them in the 6% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SITTON, JEHANNE SOUAYA receive 1.76 office actions before reaching final disposition. This places the examiner in the 35% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by SITTON, JEHANNE SOUAYA is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +60.4% benefit to allowance rate for applications examined by SITTON, JEHANNE SOUAYA. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.8% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 44.4% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 68.4% of appeals filed. This is in the 54% percentile among all examiners. Of these withdrawals, 76.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 78.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 2.6% of allowed cases (in the 78% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.4% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.